The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification

Inclusion Criteria:

- Type 2 diabetes

- Insulin naïve

- Ongoing treatment with metformin or metformin in combination with either sulphonylurea
(SU), glinides, dipeptidyl peptidase-IV (DPP-IV) inhibitors or exenatide (only twice
daily (BID))

- Glycosylated haemoglobin (HbA1c) (by central laboratory analysis): a. 7.5-10.0 % (both
inclusive) for subjects on metformin monotherapy, b. 7.0-9.0 % (both inclusive) for
subjects on metformin in combination with either SU, glinides, DPP-IV inhibitors or
exenatide (only BID)

Exclusion Criteria:

- Treatment with glucose-lowering agent(s) other than stated in the inclusion criteria
within 12 weeks

- Calcitonin equal to or above 50 pg/mL

- Stroke; heart failure New York Heart Association (NYHA) class III or IV; myocardial
infarction; unstable angina pectoris; or coronary arterial bypass graft or
angioplasty; all within 24 weeks

- Current or past (within the last 5 years) malignant neoplasms (except basal cell and
squamous cell carcinoma)